Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy

被引:11
|
作者
Altoe, Mirella L. [1 ]
Marone, Alessandro [1 ]
Kim, Hyun K. [2 ]
Kalinsky, Kevin [3 ]
Hershman, Dawn L. [3 ]
Hielscher, Andreas H. [1 ,2 ,4 ]
Ha, Richard S. [2 ]
机构
[1] Columbia Univ, Dept Biomed Engn, 500 W 120th St,Mudd Bldg,ET351, New York, NY 10027 USA
[2] Columbia Univ, Dept Radiol, Irving Med Ctr, 622 W 168th St, New York, NY 10032 USA
[3] Columbia Univ, Irving Med Ctr, Div Hematol Oncol, Dept Med, 1130 St Nicholas Ave, New York, NY 10032 USA
[4] Columbia Univ, Dept Elect Engn, 500 W 120th St,Mudd Bldg,MC 8904, New York, NY 10027 USA
基金
美国国家卫生研究院;
关键词
CONTRALATERAL NORMAL BREAST; MAMMOGRAPHIC DENSITY; TISSUE DENSITY; PATTERNS; HORMONES; VOLUME;
D O I
10.1364/BOE.10.004305
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of this study is to evaluate whether a diffuse optical tomography breast imaging system (DOTBIS) can provide a comparable optical-based image index of mammographic breast density, an established biomarker of breast cancer risk. Oxyhemoglobin concentration (ctO(2)Hb) measured by DOTBIS was collected from 40 patients with stage II-III breast cancer. The tumor-free contralateral breast was used for this evaluation. We observed a moderate positive correlation between the patient's mammogram density classification and ctO(2)Hb, r(s) = 0.486 (p = 0.001). In addition, significant reduction in ctO(2)Hb levels were noted during neoadjuvant chemotherapy treatment (p = 0.017). This observation indicates that ctO(2)Hb levels measured by DOTBIS could be a novel modifiable imaging biomarker of breast cancer risk and warrants further investigation. (C) 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
引用
收藏
页码:4305 / 4315
页数:11
相关论文
共 50 条
  • [21] Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy
    Choe, Regine
    Durduran, Turgut
    IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS, 2012, 18 (04) : 1367 - 1386
  • [22] FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer
    Qin Xie
    Ying-sheng Xiao
    Shi-cheng Jia
    Jie-xuan Zheng
    Zhen-chao Du
    Yi-chun Chen
    Mu-tong Chen
    Yuan-ke Liang
    Hao-yu Lin
    De Zeng
    Cancer Cell International, 20
  • [23] FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer
    Xie, Qin
    Xiao, Ying-Sheng
    Jia, Shi-Cheng
    Zheng, Jie-Xuan
    Du, Zhen-Chao
    Chen, Yi-Chun
    Chen, Mu-Tong
    Liang, Yuan-Ke
    Lin, Hao-Yu
    Zeng, De
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [24] The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer
    Bougnoux, Philippe
    Hajjaji, Nawale
    Couet, Charles
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2008, 79 (3-5): : 93 - 96
  • [25] Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
    Zarotti, Cristina
    Papassotiropoulos, Barbel
    Elfgen, Constanze
    Dedes, Konstantin
    Vorburger, Denise
    Pestalozzi, Bernhard
    Trojan, Andreas
    Varga, Zsuzsanna
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
    Cristina Zarotti
    Bärbel Papassotiropoulos
    Constanze Elfgen
    Konstantin Dedes
    Denise Vorburger
    Bernhard Pestalozzi
    Andreas Trojan
    Zsuzsanna Varga
    Scientific Reports, 12
  • [27] Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer
    Lee, Suji
    Kim, Jee Yeon
    Lee, So Jeong
    Hwang, Chung Su
    Lee, Hyun Jung
    Kim, Kyung Bin
    Lee, Jung Hee
    Shin, Dong Hoon
    Choi, Kyung Un
    Lee, Chang Hun
    Huh, Gi Yeong
    Kim, Ahrong
    MEDICINA-LITHUANIA, 2024, 60 (05):
  • [28] Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer
    Dawood, Shaheenah
    Gonzalez-Angulo, Ana M.
    CANCER BIOMARKERS, 2012, 12 (06) : 241 - 250
  • [29] CHANGES IN BIOMARKER STATUS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
    Matsumoto, A.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S64 - S64
  • [30] Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography
    Mirella L. Altoe
    Kevin Kalinsky
    Alessandro Marone
    Hyun K. Kim
    Hua Guo
    Hanina Hibshoosh
    Mariella Tejada
    Katherine D. Crew
    Melissa K. Accordino
    Meghna S. Trivedi
    Dawn L. Hershman
    Andreas H. Hielscher
    Breast Cancer Research, 23